Read more at The ASCO Post 9/2/2022
As reported in The Lancet Oncology, Kleppe et al have developed a risk stratification system using the DoMore-v1-CRC marker and pathologic staging markers that may permit many patients with stage II or III colorectal cancer to avoid adjuvant chemotherapy.
As stated by the investigators, “The DoMore-v1-CRC marker was recently developed using deep learning and conventional hematoxylin and eosin-stained tissue sections and was observed to outperform established molecular and morphological markers of patient outcome after primary colorectal cancer resection. The aim of the present study was to develop a clinical decision support system based on DoMore-v1-CRC and [pathologic] staging markers to facilitate individualized selection of adjuvant treatment.”
